STOCK TITAN

Matinas BioPharma Holdings, Inc. - $MTNB STOCK NEWS

Welcome to our dedicated page for Matinas BioPharma Holdings news (Ticker: $MTNB), a resource for investors and traders seeking the latest updates and insights on Matinas BioPharma Holdings stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Matinas BioPharma Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Matinas BioPharma Holdings's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
conferences
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.5%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.9%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.75%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.55%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.36%
Tags
conferences
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.37%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
conferences
Matinas BioPharma Holdings, Inc.

NYSE:MTNB

MTNB Rankings

MTNB Stock Data

42.79M
211.96M
2.53%
10.43%
1.51%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
BEDMINSTER

About MTNB

matinas biopharma (nyse mkt: mtnb) is a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications. the company's proprietary, disruptive technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, making them safer, more tolerable, less toxic and orally bioavailable. the company's lead drug candidate mat2203, currently in phase 2, is an orally-administered, encochleated formulation of amphotericin b (a broad spectrum fungicidal agent). the company has an open investigational new drug (ind) application for mat2501, currently in phase 1, which is an orally-administered, encochleated formulation of amikacin (a broad spectrum aminoglycoside antibiotic agent) for acute bacterial infections, including non-tuberculous mycobacterium (ntm) and multi-drug resistant gram negative bacterial infections. the company's lead anti-infective product candidates, mat2203 and mat2501, position matinas biopharma to bec